Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice

Neuromuscular Disorders

Volumn 20, Issue 4, 2010, Pages 260-266

  Soon, Cynthia P W ^a,b   Crouch, Peter J ^a,b   Turner, Bradley J ^a   McLean, Catriona A ^c   Laughton, Katrina M ^a,b   Atkin, Julie D ^a   Masters, Colin L ^a,b   White, Anthony R ^a,b   Li, Qiao Xin ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Amyotrophic lateral sclerosis (ALS); Matrix metalloproteinase 2 (MMP 2); Matrix metalloproteinase 9 (MMP 9); Serum; SOD1G93A transgenic mice; Superoxide dismutase 1 (SOD1); Zymography

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GELATINASE B; RECOMBINANT PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ENZYME ACTIVITY; GENE DOSAGE; GENE EXPRESSION; GENE NUMBER; GLIA; MOTOR PERFORMANCE; MOUSE; MUTANT; NEUROPIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ROTAROD TEST; SPINAL CORD MOTONEURON; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE DOSAGE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUTATION; NEUROGLIA; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 77950955450     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.11.015     Document Type: Article

References (40)

1. Kuncl R.W., Crawford T.O., Rothstein J.D., Drachman D.B. Motor neuron diseases. Diseases of the nervous system 1992, 1179-1208. WB Saunders, Philadelphia. A.K. Asbury, G.M. McKhann, W.I. McDonald (Eds.).
2. Pasinelli P., Brown R. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006, 7:710-723.
3. Rosen D.R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
4. Bruijn L.I., Houseweart M.K., Kato S., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
5. Boillee S., Vande Velde C., Cleveland D. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
6. Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004, 27:723-749.
7. Goodall E.F., Morrison K.E. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med 2006, 8:1-22.
8. Turner B.J., Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008, 85:94-134.
9. Ennis B.W., Matrisian L.M. Matrix degrading metalloproteinases. J Neurooncol 1994, 18:105-109.
10. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005, 6:931-944.
11. Ludolph A.C. Matrix metalloproteinases - a conceptional alternative for disease-modifying strategies in ALS/MND?. Exp Neurol 2006, 201:277-280.
12. Schoser B.G., Blottner D. Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle. Neuroreport 1999, 10:2795-2797.
13. Lim G.P., Backstrom J.R., Cullen M.J., Miller C.A., Atkinson R.D., Tokes Z.A. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem 1996, 67:251-259.
14. Beuche W., Yushchenko M., Mader M., Maliszewska M., Felgenhauer F., Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000, 11:3419-3422.
15. Demestre M., Parkin-Smith G., Petzold A., Pullen A.H. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol 2005, 159:146-154.
16. Lorenzl S., Albers D.S., Relkin N., et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 2003, 43:191-196.
17. Lorenzl S., Albers D.S., LeWitt P.A., et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003, 207:71-76.
18. Lorenzl S., Narr S., Angele B., et al. The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Exp Neurol 2006, 200:166-171.
19. Kiaei M., Kipiani K., Calingasan N.Y., et al. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2007, 205:74-81.
20. Dewil M., Schurmans C., Starckx S., Opdenakker G., Van Den Bosch L., Robberecht W. Role of matrix metalloproteinase-9 in a mouse model for amyotrophic lateral sclerosis. Neuroreport 2005, 16:321-332.
21. Feeney S.J., McKelvie P.A., Austin L., et al. Presymptomatic motor neuron loss and reactive astrocytosis in the SOD1 mouse model of amyotrophic lateral sclerosis. Muscle Nerve 2001, 24:1510-1519.
22. Li Q.X., Mok S.S., Laughton K.M., et al. Overexpression of Abeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell 2006, 5:153-165.
23. Turner B.J., Cheah I.K., Macfarlane K.J., et al. Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neurochem 2003, 87:752-763.
24. Snoek-van Beurden P.A., Von den Hoff J.W. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005, 38:73-83.
25. Gurney M.E., Pu H., Chiu A.Y., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
26. Mantuano E., Inoue G., Li X., et al. The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J Neurosci 2008, 28:11571-11582.
27. Dzwonek J., Rylski M., Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 2004, 567:129-135.
28. Ilzecka J., Stelmasiak Z., Dobosz B. Matrix metalloproteinase-9 (MMP-9) activity in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol Neurochir Pol 2001, 35:1035-1043.
29. Kherif S., Dehaupas M., Lafuma C., Fardeau M., Alameddine H.S. Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve. Neuropathol Appl Neurobiol 1998, 24:309-319.
30. Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
31. Muir E.M., Adcock K.H., Morgenstern D.A., et al. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 2002, 100:103-117.
32. Yin K.J., Cirrito J.R., Yan P., et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 2006, 26:10939-10948.
33. Chakraborti S., Mandal M., Das S., Mandal A., Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253:269-285.
34. Menzies F.M., Cookson M.R., Taylor R.W., et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002, 125:1522-1533.
35. Pasinelli P., Belford M.E., Lennon N., et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004, 43:19-30.
36. Vijayvergiya C., Beal M.F., Buck J., Manfredi G. Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci 2005, 25:2463-2470.
37. Nelson K.K., Melendez J.A. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004, 37:768-784.
38. Yu F., Kamada H., Niizuma K., Endo H., Chan P.H. Induction of mmp-9 expression and endothelial injury by oxidative stress after spinal cord injury. J Neurotrauma 2008, 25:184-195.
39. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511.
40. Ryberg H., Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev Proteomics 2008, 5:249-262.